Statin therapy is a treatment with a proven positive impact on survival after heart
transplantation. However, it is unclear whether the beneficial effect of this class of drugs
depends solely on their LDL-lowering properties or on anti-inflammatory and immuno-modulatory
properties. Thus, this study was designed to compare safety and efficacy of two different
strategies: 1. high fixed statin dose vs. 2. low starting dose with LDL-driven doses
adjustments.
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
Completed
US Department of Veterans Affairs
Phase 2
2007-06-01
Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy.
Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans
Administration. It is a randomized control format including genotypes 1 and 3. There will
also be pilot arms for HCV carriers who present for screening already on a statin, who will
be allowed to stay on their current statin or switched to another statin. In all ways,
standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package
insert.
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
Completed
VA Office of Research and Development
Phase 2
2007-06-01
Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy.
Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans
Administration. It is a randomized control format including genotypes 1 and 3. There will
also be pilot arms for HCV carriers who present for screening already on a statin, who will
be allowed to stay on their current statin or switched to another statin. In all ways,
standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package
insert.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
